Circulating tumor cells and CDX models as a tool for preclinical drug development

Area of Science:

• Oncology
• Cancer Research
• Translational Medicine

Background:

• Lung cancer remains a leading cause of cancer mortality globally.
• Existing research models like cell lines and genetically engineered mouse models (GEMMs) have limitations in improving clinical outcomes.
• Patient-derived xenograft (PDX) models show promise for personalized therapy but involve invasive patient biopsies.

Purpose of the Study:

• To discuss the potential of circulating tumor cell (CTC)-derived models in lung cancer research.
• To highlight the advantages of liquid biopsies for generating novel preclinical models.
• To explore challenges and opportunities in utilizing CTC-derived models, particularly for small cell lung cancer (SCLC).

Main Methods:

• Utilizing liquid biopsies for non-invasive collection of circulating tumor cells (CTCs).
• Generating patient-derived models from CTCs to recapitulate tumor heterogeneity.
• Reviewing existing literature on CTC-derived models in lung cancer, with a focus on SCLC.

Main Results:

• Liquid biopsies provide a rapid, non-invasive method to obtain tumor surrogates.
• CTCs from a single blood draw can reflect the molecular diversity of primary tumors.
• CTC-derived models are emerging as valuable preclinical tools, especially for SCLC.

Conclusions:

• CTC-derived models represent a significant advancement in preclinical lung cancer research.
• These models offer a promising avenue for personalized therapy approaches.
• Further development is needed to overcome challenges and fully leverage CTC-derived models in clinical settings.